Faron Pharmaceuticals Oy (FARN)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

155.00p

Buy

160.00p

arrow-down-17.50p (-10.00%)

Prices updated at 16 Dec 2025, 15:03 GMT

Prices minimum 15 mins delay

Prices in GBX

Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company developing novel treatments for medicalconditions. The company currently has a pipeline focusing on acute organ traumas,vascular damage and cancer immunotherapy.

FTSE All-Share

-0.71%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Tuomo Tapani Patsi

CEO

-

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

32

Head office

Joukahaisenkatu 6 B

Turku

Finland

20520

+358 24695151

investor.relations@faron.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Tuomo Tapani Patsi Non-Executive Director, Chairman	-
Mr. John Poulos Non-Executive Director	-
Dr. Marie-Louise Helena Fjallskog Non-Executive Director	-
Ms. Christine Ann Roth Non-Executive Director	-
Dr. Markku Tapani Jalkanen Executive Director	-
Dr. Juho Markku Jalkanen Executive Director	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
OP-Rahastoyhtiö Oy	1,854,201
OP-Suomi	1,854,201
Sp-Rahastoyhtiö Oy	1,575,042
Danske Invest Rahastoyhtiö Oy	1,305,262
Danske Invest Suomi Osake	1,305,262

Director dealings

Date chevron-l-regular chevron-r-regular	Action
27 Jun 2025	Purchase
27 Jun 2025	Purchase
03 Jun 2025	Transfer out
03 Jun 2025	Transfer out
03 Jun 2025	Sale
03 Jun 2025	Sale

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.